Canandaigua National Bank & Trust Co. Has $4.65 Million Stock Holdings in CVS Health Co. (NYSE:CVS)

Canandaigua National Bank & Trust Co. lowered its position in shares of CVS Health Co. (NYSE:CVSFree Report) by 2.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 58,291 shares of the pharmacy operator’s stock after selling 1,495 shares during the quarter. Canandaigua National Bank & Trust Co.’s holdings in CVS Health were worth $4,649,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Atticus Wealth Management LLC raised its holdings in shares of CVS Health by 149.0% in the fourth quarter. Atticus Wealth Management LLC now owns 366 shares of the pharmacy operator’s stock valued at $29,000 after buying an additional 219 shares during the last quarter. USA Financial Formulas raised its holdings in shares of CVS Health by 573.2% in the fourth quarter. USA Financial Formulas now owns 377 shares of the pharmacy operator’s stock valued at $30,000 after buying an additional 321 shares during the last quarter. Ables Iannone Moore & Associates Inc. acquired a new stake in CVS Health in the fourth quarter worth about $32,000. Creekmur Asset Management LLC acquired a new stake in CVS Health in the fourth quarter worth about $34,000. Finally, Kapitalo Investimentos Ltda acquired a new stake in CVS Health in the fourth quarter worth about $36,000. 80.66% of the stock is owned by institutional investors.

Insider Transactions at CVS Health

In other CVS Health news, Director Edward J. Ludwig purchased 1,000 shares of CVS Health stock in a transaction dated Thursday, May 2nd. The stock was acquired at an average price of $53.88 per share, for a total transaction of $53,880.00. Following the acquisition, the director now owns 21,630 shares in the company, valued at approximately $1,165,424.40. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.24% of the company’s stock.

CVS Health Stock Performance

Shares of CVS stock traded up $0.29 on Tuesday, reaching $61.38. The stock had a trading volume of 4,773,542 shares, compared to its average volume of 12,077,454. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. CVS Health Co. has a 1 year low of $52.77 and a 1 year high of $83.25. The stock has a market cap of $77.05 billion, a P/E ratio of 10.72, a price-to-earnings-growth ratio of 0.57 and a beta of 0.53. The company has a 50 day simple moving average of $61.24 and a 200 day simple moving average of $70.90.

CVS Health (NYSE:CVSGet Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The pharmacy operator reported $1.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.38). The firm had revenue of $88.44 billion during the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a return on equity of 13.53% and a net margin of 2.03%. The business’s revenue for the quarter was up 3.7% on a year-over-year basis. During the same period last year, the company earned $2.20 earnings per share. Equities research analysts expect that CVS Health Co. will post 7.02 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Monday, April 22nd were given a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 4.33%. The ex-dividend date was Friday, April 19th. CVS Health’s dividend payout ratio is currently 46.75%.

Wall Street Analyst Weigh In

A number of analysts recently commented on CVS shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $58.00 price objective on shares of CVS Health in a research report on Wednesday, June 12th. JPMorgan Chase & Co. decreased their target price on CVS Health from $101.00 to $86.00 and set an “overweight” rating for the company in a research report on Thursday, May 30th. Argus decreased their target price on CVS Health from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. TD Cowen cut CVS Health from a “buy” rating to a “hold” rating and cut their price objective for the company from $99.00 to $59.00 in a report on Tuesday, May 7th. Finally, UBS Group cut CVS Health from a “buy” rating to a “neutral” rating and cut their price objective for the company from $85.00 to $60.00 in a report on Thursday, May 2nd. Eleven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $75.05.

Check Out Our Latest Report on CVS

About CVS Health

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Featured Stories

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.